SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* TETI NICHOLAS (Last) (First) (Middle) 2800 PATTON ROAD (Street) MINNEAPOLIS MN 55113 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol EnteroMedics Inc [ ETRM ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 09/30/2010
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
No securities are held								000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$44.77(4)							04/27/2007(1)	04/27/2017	Common Stock	4,578(4)		4,578(4)	D
Stock Option (right to buy)	$26.41(4)							05/06/2008(1)	05/06/2018	Common Stock	1,666(4)		1,666(4)	D
Stock Option (right to buy)	$11.58(4)							05/05/2009(1)	05/05/2019	Common Stock	1,666(4)		1,666(4)	D
Stock Option (right to buy)	$13.8(4)							05/28/2009(2)	05/28/2019	Common Stock	25,000(4)		25,000(4)	D
Stock Option (right to buy)	$3.24(4)							02/10/2010(3)	02/10/2020	Common Stock	12,500(4)		12,500(4)	D
Stock Option (right to buy)	$2.52(4)							05/06/2010(1)	05/06/2020	Common Stock	1,666(4)		1,666(4)	D
Series A NonVoting Convertible Preferred Stock	(5)	09/30/2010		P		10,840		09/30/2010	(6)	Common Stock	10,840	$1.72	10,840	D
Up Front Warrant	$2.15	09/30/2010		P		10,840		(7)	(6)	Common Stock	10,840	$0.125	10,840	D

Explanation of Responses:

1. Vests as to 25% on date noted and thereafter in cumulative installments of 1/36th per month.

2. Vests in cumulative installments of 1/36th per month beginning the date shown.

3. 25,0000 shares vest immediately and the remaining 50,000 shares vest in cumulative installments of 1/36th per month beginning 3/10/2010.

4. On July 9, 2010, EnteroMedics Inc. effected a 1-for-6 reverse stock split of its issued and outstanding shares of common stock, par value $0.01 per share, resulting in a proportional decrease in the total shares of common stock beneficially owned by the reporting person. All previously reported exercise prices, options grants and similar instruments convertible into common stock were proportionally adjusted to reflect the reverse split.

5. The Series A preferred stock is convertible into EnterMedics common stock on a 1-for-1 basis. Upon the completion of certain financings, as described in the Certificate of Designations, additional conversion warrants may be issued. If the converson warrants are issued by the Company, the reporting person would pay $0.125 per conversion warrant with such warrant price to be paid through an adjustment to the conversion.

6. Not applicable.

7. The later of six months from the date of issuance, or the completion of a financing described in the certificate of designations.

Remarks:

THIS FILING REFLECTS THE POST SPLIT NUMBERS OF ALL SHARES, OPTIONS AND SIMILAR INSTRUMENTS HELD BY THE REPORTING PERSON AS PREVIOUSLY REPORTED.

	/s/ Greg S. Lea, Attorney-in-Fact	10/01/2010
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.